secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001628280-22-017806
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus amends CartiHeal acquisition, defers $215M upfront, lowers sales milestone to $75M
--------------------------------------------------------------------------------

- Deferred $215M of $315M upfront; paid in five tranches 2023–2027 with 8% annual interest.
- Contingent ~$135M now triggered at $75M trailing sales (down from $100M).
- Expected close by end of July 2022; upfront ~$100M (incl. $50M escrowed).
- Bioventus to pay ~$8M of CartiHeal's transaction fees.
- Additional milestones: First Paper $50M, Additional Publication $25M, etc., with interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022017806/0001628280-22-017806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022017806/bvs-20220617.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-017806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer